Quarter
Charts

NRX PHARMACEUTICALS, INC.

NRXP

CIK 0001719406 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$983K
Gross Profit
$575K

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Weak
33/100
  • Profitability
    100ROIC 65.5% (10% = solid, 20%+ = moat)
  • Liquidity
    0Current Ratio 0.31 (above 1.5 = solid)
  • Leverage
    100D/E -0.78 (under 0.5 = conservative)
  • Efficiency
    0Asset Turnover 0.15x (1.0+ = capital-efficient)
  • Growth
    0Insufficient data
  • Margin Trend
    0Insufficient data

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$0
investment in PP&E
Stock buybacks (TTM)
—
share count reduction
Stock-based comp (TTM)
$228K
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$13M
everything owned
Total liabilities
$29M
everything owed
Stockholders' equity
$-16M
shareholder claim
Net debt
$1M
LT debt minus cash

Recent performance · 33 quarters

Revenue
$983K
Net Income↓-262.9% -$4M
$-6M
Free Cash Flow↑+5.2% +$191K
$-3M
Operating Margin
-1662.8%

Drill down

NRXP Sankey

See NRX PHARMACEUTICALS, INC.'s revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

NRXP Charts

33 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

NRXP Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics